310 results on '"Cappelletti, Vera"'
Search Results
2. A gene expression-based classifier for HER2-low breast cancer
3. Isolation and Genomic Analysis of Circulating Tumor Cell Clusters in Cancer Patients
4. Clinical and Biological Significance of HER2-Low in Ductal Carcinoma In Situ of the Breast
5. Can we define breast cancer HER2 status by liquid biopsy?
6. Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients
7. Copy number alterations analysis of primary tumor tissue and circulating tumor cells from patients with early-stage triple negative breast cancer
8. Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs
9. Advancing Circulating Tumor DNA for Recurrent Breast Cancer
10. A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluation of ARv7 in mCRPC patients with measurable metastases including visceral disease (Excalibur study)
11. Sorafenib Versus Observation Following Radical Metastasectomy for Clear-cell Renal Cell Carcinoma: Results from the Phase 2 Randomized Open-label RESORT Study
12. Acquired Resistance Mechanisms to PD-L1 Blockade in a Patient With Microsatellite Instability-High Extrahepatic Cholangiocarcinoma
13. Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen
14. Direct and indirect effects of COVID-19 on short-term mortality of breast cancer patients
15. Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs
16. Development of a Protocol for Single-Cell Analysis of Circulating Tumor Cells in Patients with Solid Tumors
17. DESTINY-Breast03 trial: some questions remain
18. Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast
19. List of Contributors
20. Gene Profiles in Breast Cancer
21. Experimental workflow from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
22. Supplementary Figure 2 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
23. Supplementary Figure 5 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
24. Supplementary Table 3 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
25. Supplementary Methods, Results and Tables from Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
26. Supplementary Figure 4 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
27. Supplementary Figure 1 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
28. Cut-off determination and representative staining profiles for eIF proteins determined by immunohistochemistry from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
29. Supplementary Table 1 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
30. Interrogation of Oncomine{trade mark, serif} from A Case-Matched Gender Comparison Transcriptomic Screen Identifies eIF4E and eIF5 as Potential Prognostic Markers in Male Breast Cancer
31. Supplementary Table 2 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
32. Supplementary Figures from Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer
33. Supplementary Figure 3 from Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
34. Comprehensive transcriptomic analysis to identify biological and clinical differences in cholangiocarcinoma
35. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
36. Association of Hormone Receptors With Clinical Outcomes in Patients With ERBB2-Low Breast Cancer
37. Concomitant medications and circulating tumor cells: friends or foes?
38. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world
39. Cell cycle dependent oscillatory expression of estrogen receptor-α links Pol II elongation to neoplastic transformation
40. Biomarkers for Breast Cancer: Towards the Proposition of Clinically Relevant Tools
41. Prognostic and functional role of subtype‐specific tumor–stroma interaction in breast cancer
42. Single-Cell Phenotypic and Molecular Characterization of Circulating Tumor Cells Isolated from Cryopreserved Peripheral Blood Mononuclear Cells of Patients with Lung Cancer and Sarcoma
43. Additional file 1 of Gene signatures of circulating breast cancer cell models are a source of novel molecular determinants of metastasis and improve circulating tumor cell detection in patients
44. Assessing HER2 status in breast cancer through next-generation sequencing of circulating tumor cells.
45. Integrated Molecular and Immune Phenotype of HER2-Positive Breast Cancer and Response to Neoadjuvant Therapy: A NeoALTTO Exploratory Analysis
46. Did circulating tumor cells tell us all they could? The missed circulating tumor cell message in breast cancer
47. Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab
48. Abstract 586: Expression of CD68 on CKpos/CD45poscirculating cells in breast cancer patients: An additional hint supporting the fusion hybrid theory
49. A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.
50. Circulating Tumor Cell Clusters Are Frequently Detected in Women with Early-Stage Breast Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.